This study is for people with type 1 or type 2 diabetes who are starting insulin therapy when they leave the hospital. It compares two ways to manage blood sugar: wearing a Continuous Glucose Monitor (CGM) for two weeks, or using a standard Blood Glucose Monitor (BGM) for two weeks. The goal is to see if using a CGM helps improve your Hemoglobin A1c (HbA1c), which is a measure of your average blood sugar over the past few months. We are looking for 150 participants aged 18 to 100 years who are admitted to NYU Langone Hospital - Long Island and are new to insulin. The study's current status is unclear.

Study design

This is a randomized study involving 120 participants. You would be assigned to either wear a Continuous Glucose Monitor or use a Blood Glucose Monitor.

What's involved

You would wear a monitoring device for 2 weeks. There will be a 2-week follow-up visit and a 3-month follow-up visit where your HbA1c will be measured.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for 3 months after hospital discharge to measure changes in HbA1c.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.